The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Distinct molecular features and potential therapeutic strategies for spinal cord gliomas.
 
Frances Elaine Chow
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Patricia Pittman
No Relationships to Disclose
 
Edith Yuan
No Relationships to Disclose
 
Tania Vartanians
No Relationships to Disclose
 
Phillip Walker
Employment - Caris Life Sciences
 
Theodore Nicolaides
Employment - Caris Life Sciences
 
Michael J. Glantz
Research Funding - cns pharmaceuticals (Inst); Denovo Biopharma (Inst); European Organisation for Research and Treatment of Cancer (EORTC) (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmunoCellular Therapeutics (Inst); Ono Pharmaceutical (Inst); RTOG (Inst); Triphase Accelerator Corp (Inst)
 
Ashley Love Sumrall
Honoraria - Cardinal Health; Curio Science; Gerson Lehrman Group
Consulting or Advisory Role - Abbvie; Amgen; Athenex; Bayer; Exelixis; Merck; Novocure
Speakers' Bureau - Abbvie; Bayer; Bristol-Myers Squibb; Exelixis; Merck; Novocure; Prime Oncology
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Kura Oncology (Inst); Novocure (Inst); Oncoceutics (Inst)
Travel, Accommodations, Expenses - American Association of Neurological Surgeons; Bristol-Myers Squibb; Novocure; Xcenda
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences
 
Sonikpreet Aulakh
No Relationships to Disclose
 
David M. Ashley
Stock and Other Ownership Interests - Diverse Biotech; MAIA Biotechnology
Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; MAIA Biotechnology
Patents, Royalties, Other Intellectual Property - Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/787,508 filed January 2, 2019 Methods for predicting tumor response to immunotherapy, U.S. Provisional application no. 62/620,577 filed January 23, 2018
 
David Spetzler
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Caris Life Sciences
Research Funding - Caris Life Sciences
Patents, Royalties, Other Intellectual Property - Caris Life Sciences holds and has pending patents with intellectual property interests relating to health and medicine.
Travel, Accommodations, Expenses - Caris Life Sciences
 
Lindsay Hwang
No Relationships to Disclose
 
Jason Chao Ye
No Relationships to Disclose
 
Eric L. Chang
No Relationships to Disclose
 
James S Hu
No Relationships to Disclose
 
Frank J. Attenello
No Relationships to Disclose
 
Josh Neman
No Relationships to Disclose
 
David D. Tran
Honoraria - Novocure
Consulting or Advisory Role - Novocure
Research Funding - Lacerta Therapeutics; Merck; Monteris Medical; Novocure; Sarepta Therapeutics
Patents, Royalties, Other Intellectual Property - A molecular cell diary system; AAV capsid variants targeting human glioblastoma stem-like cells; Chemotherapeutic resensitization of disseminated cancer stem cells through reactivation by p38 inhibition and IL-6 inhibition - chemotherapeutic methods; Core master regulators of glioblastoma stem cells; Direct conversion of human mesenchymal stem cells to human cardiomyocytes; GeneRep and nSCORE: Method and apparatus for improved determination of node influence in a network; Immunotherapy for direct reprogramming of cancer cells into immune cells/antigen presenting cells/dendritic cells; Inhibiting prostaglandin e receptor 3 resensitizes resistant cells to TTFields and prevents cells from developing resistance to TTFields; Methods and compositions for determining susceptibility to treatment with checkpoint inhibitors; Methods for cancer screening and monitoring by cancer master regulators markers in liquid biopsy; Methods for reducing viability of cancer cells by activation of the STING pathway with TTFields; Methods for targeted treatment and prediction of patient survival in cancer
Travel, Accommodations, Expenses - Novocure
 
Gabriel Zada
Consulting or Advisory Role - Integra LifeSciences; Stryker